Turn Therapeutics Inc. (TTRX)

Turn Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cost of Revenue	0.5	-	-	-
Gross Profit	-0.5	-	-	-
Selling, General & Admin	5.59	1.55	2.3	4.21
Research & Development	0.27	0.25	0.01	-
Operating Expenses	5.86	1.8	2.31	4.21
Operating Income	-6.36	-1.8	-2.31	-4.21
Interest Expense	-	-	-	-0.09
Interest & Investment Income	0.03	0.03	0.02	0.01
Other Non Operating Income (Expenses)	3.13	-	-	-
Pretax Income	-3.19	-1.77	-2.29	-4.29
Income Tax Expense	-	-	-	0
Net Income	-3.19	-1.77	-2.29	-4.29
Net Income to Common	-3.19	-1.77	-2.29	-4.29
Shares Outstanding (Basic)	28	27	26	-
Shares Outstanding (Diluted)	28	27	26	-
Shares Change (YoY)	4.03%	0.56%	-	-
EPS (Basic)	-0.12	-0.07	-0.09	-
EPS (Diluted)	-0.12	-0.07	-0.09	-
EBITDA	-6.3	-1.75	-2.26	-4.16
D&A For EBITDA	0.05	0.05	0.04	0.05
EBIT	-6.36	-1.8	-2.31	-4.21

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q